Symbicort Turbuhaler 160 mcg/dose, Dihydrate 4.5 mcg/dose

Šalis: Jordanija

kalba: anglų

Šaltinis: JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

Veiklioji medžiaga:

Budesonide 160 mcg/dose, Formoterol Fumarate Dihydrate 4.5 mcg/dose

Prieinama:

مستودع ادوية شاوي و رشيدات و مسنات - Shawi & Rushedat Drug Store

ATC kodas:

R03BA02

INN (Tarptautinis Pavadinimas):

Budesonide 160 mcg/dose, Formoterol Fumarate Dihydrate 4.5 mcg/dose

Dozė:

160 mcg/dose, Dihydrate 4.5 mcg/dose

Vienetai pakuotėje:

60 dose

Pagaminta:

AstraZeneca (السويد)

Produkto santrauka:

19.85 :سعر الجمهور + الضريبة

Pakuotės lapelis

Profile
Technical Info
N/A
6350
AZL030I
PS19307
30-11-2020
104605892/402120374 0020
Symbicort TBH Leaflet professional
160/4.5mcg Standard English
SGK is a Matthews International Corporation
Black
BODY TEXT SIZE
10.0 pt
SMALLEST TEXT SIZE
6.0 pt
Symbicort Turbuhaler
160/4.5 µg/dose
_budesonide/formoterol_
Inhalation powder
Composition
Each delivered dose (the dose that leaves the mouthpiece) contains:
budesonide 160 micrograms/inhalation and formoterol fumarate dihydrate
4.5 micrograms/inhalation.
Symbicort Turbuhaler 160/4.5 micrograms/inhalation delivers the same
amount
of budesonide and formoterol as the corresponding Turbuhaler
monoproducts,
i.e. budesonide 200 micrograms/inhalation (metered dose) and
formoterol
6 micrograms/inhalation (metered dose) alternatively labelled as
4.5 micrograms/inhalation (delivered dose).
Excipient: Lactose monohydrate 730 micrograms per dose.
Therapeutic indications
Asthma
Symbicort Turbuhaler is indicated in adults and adolescents (12 years
and
older) for the regular treatment of asthma where use of a combination
(inhaled corticosteroid and long-acting
beta
2
-agonist) is appropriate:
-
patients not adequately controlled with inhaled corticosteroids and
“as needed” inhaled short-acting
beta
2
-agonists
or
-
patients already adequately controlled on both inhaled corticosteroids
and long-acting beta
2
-agonists.
COPD
Symbicort Turbuhaler is indicated in adults, and 18 years and older,
for the symptomatic treatment of patients
with COPD with forced expiratory volume in 1 second (FEV
1
)
<70% predicted normal, (post bronchodilator) and
an exacerbation history despite regular bronchodilator therapy.
Posology and method of administration
Asthma
Symbicort is not intended for the initial management of asthma. The
dosage of the components of Symbicort
is individual and should be adjusted to the severity of the disease.
This should be considered not only when
treatment with combination products is initiated but also when the
maintenance dose is adjusted. If an
individual patient sh